Ken Griffin Diagnostics & Research

Citadel Advisors LLC

$550 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
TMO Thermo Fisher Scientific Inc.	$187B	$445 Million 0.08% of portfolio	1,096,823	Q2 2025 Added 809.68%
ICLR Icon PLC	$13.8B	$283 Million 0.05% of portfolio	1,946,142	Q2 2025 Added 175.92%
A Agilent Technologies, Inc.	$34.7B	$194 Million 0.04% of portfolio	1,647,899	Q2 2025 Reduced 21.45%
GH Guardant Health, Inc.	$5.63B	$153 Million 0.03% of portfolio	2,938,553	Q2 2025 Reduced 18.3%
NTRA Natera, Inc.	$15.5B	$139 Million 0.03% of portfolio	821,445	Q2 2025 Reduced 61.31%
CRL Charles River Laboratories International, Inc.	$7.77B	$85.7 Million 0.02% of portfolio	564,591	Q2 2025 Added 100.2%
TWST Twist Bioscience Corp	$1.55B	$55.3 Million 0.01% of portfolio	1,503,546	Q2 2025 Added 40.35%
IDXX Idexx Laboratories Inc	$54.3B	$23.3 Million 0.0% of portfolio	43,382	Q2 2025 Added 3,946.83%
EXAS Exact Sciences Corp	$7.33B	$23.1 Million 0.0% of portfolio	435,503	Q2 2025 Added 90.13%
MEDP Medpace Holdings, Inc.	$14.2B	$21.7 Million 0.0% of portfolio	69,002	Q2 2025 New
CSTL Castle Biosciences Inc	$509M	$18.1 Million 0.0% of portfolio	888,515	Q2 2025 Added 243.88%
DHR Danaher Corp	$150B	$17.2 Million 0.0% of portfolio	86,952	Q2 2025 Reduced 96.7%
CDNA Care Dx, Inc.	$666M	$15.4 Million 0.0% of portfolio	790,667	Q2 2025 Reduced 0.4%
NEOG Neogen Corp	$1.13B	$13.2 Million 0.0% of portfolio	2,753,577	Q2 2025 Added 137,578.84%
FLGT Fulgent Genetics, Inc.	$636M	$12 Million 0.0% of portfolio	603,653	Q2 2025 Added 38.53%
MYGN Myriad Genetics Inc	$486M	$9.09 Million 0.0% of portfolio	1,711,021	Q2 2025 Added 219.74%
NEO Neogenomics Inc	$765M	$4.27 Million 0.0% of portfolio	583,848	Q2 2025 Added 314.5%
DGX Quest Diagnostics Inc	$15.6B	$3.85 Million 0.0% of portfolio	28,095	Q2 2025 Reduced 79.35%
RDNT Rad Net, Inc.	$3.64B	$3.31 Million 0.0% of portfolio	58,242	Q2 2025 Reduced 28.04%
ILMN Illumina, Inc.	$15.3B	$2.57 Million 0.0% of portfolio	26,889	Q2 2025 Reduced 91.23%
SERA Sera Prognostics, Inc.	$66M	$1.74 Million 0.0% of portfolio	629,007	Q2 2025 Added 0.26%
ACRS Aclaris Therapeutics, Inc.	$109M	$1.62 Million 0.0% of portfolio	1,143,806	Q2 2025 Added 1.94%
PKI Perkinelmer Inc	$15.3B	$1.56 Million 0.0% of portfolio	12,882	Q2 2025 New
WAT Waters Corp	$17.1B	$1.2 Million 0.0% of portfolio	3,447	Q2 2025 Reduced 77.32%
IQV Iqvia Holdings Inc.	$34.5B	$1.03 Million 0.0% of portfolio	6,525	Q2 2025 Reduced 94.32%
SHC Sotera Health CO	$4.18B	$978,000 0.0% of portfolio	88,037	Q2 2025 Added 22.81%
LAB Standard Biotools Inc.	$103M	$418,000 0.0% of portfolio	349,160	Q2 2025 New
OPK Opko Health, Inc.	$1.02B	$286,000 0.0% of portfolio	217,395	Q2 2025 Reduced 88.29%
NOTV Inotiv, Inc.	$51.2M	$238,000 0.0% of portfolio	130,863	Q2 2025 Added 69.63%
VNRX Volitionrx LTD	$36.1M	$147,000 0.0% of portfolio	193,745	Q2 2025 New

Shares Options

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Ken Griffin's portfolio

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account